Trial of Magnesium Sulfate Tocolysis Versus Nifedipine Tocolysis in Women With Preterm Labor
This study has been terminated.
(No enrollment in past year, lack of interest)
Sponsor:
University of Cincinnati
Collaborator:
University Hospital
Information provided by:
University of Cincinnati
ClinicalTrials.gov Identifier:
NCT00306462
First received: March 21, 2006
Last updated: November 6, 2009
Last verified: November 2009
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Primary Hypothesis:
Acute tocolysis (48 hours) using oral nifedipine is more effective than intravenous magnesium sulfate in prolonging pregnancy in women with preterm labor with intact membranes between 24 and 32 6/7 weeks' gestation.
| Condition | Intervention |
|---|---|
|
Premature Birth Premature Labor |
Drug: Magnesium sulfate Drug: Oral Nifedipine or placebo |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator) Primary Purpose: Treatment |
| Official Title: | Randomized Double-Blinded Trial of Magnesium Sulfate Tocolysis Versus Nifedipine Tocolysis in Women With Preterm Labor Between 24 to 32 6/7 Weeks' Gestation |
Resource links provided by NLM:
Further study details as provided by University of Cincinnati:
Primary Outcome Measures:
- Delivery <37 weeks' gestation, Delivery <34 weeks' gestation, Delivery <32 weeks' gestation [ Time Frame: 4 years ] [ Designated as safety issue: Yes ]
Secondary Outcome Measures:
- Maternal complications associated with each drugs. Neonatal morbidities associated with prematurity [ Time Frame: 4 years and 9 months ] [ Designated as safety issue: Yes ]
| Enrollment: | 33 |
| Study Start Date: | March 2006 |
| Study Completion Date: | October 2009 |
| Primary Completion Date: | October 2009 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: 1
Intravenous magnesium sulfate or placebo
|
Drug: Magnesium sulfate
Intravenous magnesium sulfate 6g bolus, then increased by 1 g/hour till a maximum of 5g/hour; gradually wean down to 2 g/hour for a total of 48 hours once uterine contractions is < 6/hour.
|
|
Active Comparator: 2
Oral nifedipine or placebo
|
Drug: Oral Nifedipine or placebo
Oral nifedipine or placebo at 20 mg every 30 minutes for the first hour, then 20 mg every 3 to 6 hours not to exceed 180 mg in 24 hours, keep maintenance dose at 20 mg every 3 to 6 hours for a total of 48 hours if uterine contractions is < 6/hour.
Other Name: Oral procardia
|
Detailed Description:
Primary Objective:
To compare the efficacy of oral nifedipine versus IV magnesium sulfate on the rate of preterm delivery at <37 weeks in women with preterm labor between 24 and 32 6/7 weeks gestation.
Secondary Objective:
- To compare maternal side effects between the two tocolytic agents
- To compare neonatal morbidities between the two study groups.
Eligibility| Ages Eligible for Study: | 15 Years to 50 Years |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:
- Women in preterm labor between 24 to 32 6/7 weeks' gestation with intact membranes with an age range of 15 to 50 years old.
Exclusion Criteria:
- Cervical dilatation of ≥ 6 cm
- Maternal contraindication to tocolysis
- Known fetal anomalies
- Suspected chorioamnionitis
- Nonreassuring fetal heart tracing
- Vaginal bleeding due to placenta previa or abruptio placenta
- Preterm premature rupture of membranes
- Prolapsed membranes
- Human immunodeficiency virus positive
- Multiple gestation
- Patients on procardia within 24 hours of po intake
- Magnesium sulfate tocolysis prior to randomization
- Patient refusal
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00306462
Locations
| United States, Ohio | |
| University Hospital | |
| Cincinnati, Ohio, United States, 45219 | |
Sponsors and Collaborators
University of Cincinnati
University Hospital
Investigators
| Principal Investigator: | Baha Sibai, MD | University of Cincinnati |
More Information
Publications:
| Responsible Party: | Baha Sibai, MD/Professor, University of Cincinnati |
| ClinicalTrials.gov Identifier: | NCT00306462 History of Changes |
| Other Study ID Numbers: | 05-12-27-01 |
| Study First Received: | March 21, 2006 |
| Last Updated: | November 6, 2009 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by University of Cincinnati:
|
Premature Labor Premature Birth Magnesium sulfate Nifedipine |
Additional relevant MeSH terms:
|
Obstetric Labor, Premature Premature Birth Obstetric Labor Complications Pregnancy Complications Magnesium Sulfate Nifedipine Analgesics Sensory System Agents Peripheral Nervous System Agents Physiological Effects of Drugs Pharmacologic Actions Central Nervous System Agents |
Therapeutic Uses Anesthetics Central Nervous System Depressants Anti-Arrhythmia Agents Cardiovascular Agents Anticonvulsants Calcium Channel Blockers Membrane Transport Modulators Molecular Mechanisms of Pharmacological Action Tocolytic Agents Reproductive Control Agents Vasodilator Agents |
ClinicalTrials.gov processed this record on May 23, 2013